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OBJECTIVE—The barrier function of the glomerular ﬁlter has
been studied for decades. Albuminuria reﬂects a malfunction of
this barrier, and in animals dysfunctional endothelial nitric-oxide
(NO) synthase results in albuminuria. We aimed to analyze the
importance of NO for the glomerular barrier function in humans.
RESEARCH DESIGN AND METHODS—To assess the effect
of endothelial dysfunction on albuminuria, we measured the
urine albumin-to-creatinine ratio (UACR) both before and after
the blockade of NO synthases (NOSs) with systemic infusion
of N
G-monomethyl-L-arginine (L-NMMA) in two distinct study
populations. In population A, 62 hypertensive patients with type
2 diabetes and, in population B, 22 patients with hypercholester-
olemia but without hypertension or type 2 diabetes were exam-
ined. All subjects had normal renal function.
RESULTS—There was a signiﬁcant increase in the UACR in
response to NOS inhibition with L-NMMA in hypertensive patients
with type 2 diabetes (study population A) and in patients with
hypercholesterolemia (study population B). Linear regression
analyses revealed that the change in mean arterial presssure in
response to L-NMMA was not related to the increase in the UACR
in response to L-NMMA in either population, even after adjusting
for ﬁltration fraction.
CONCLUSIONS—NOS inhibition provokes albuminuria that is
unrelated to changes in blood pressure. It is noteworthy that
this ﬁnding was evident in patient groups prone to endothelial
dysfunction and albuminuria. Thus, acute deterioration of endo-
thelial function by reducing NO activity causes an increase in
albuminuria. Diabetes 60:572–576, 2011
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lbuminuria predicts renal disease progression
and cardiovascular risk (1–3). There is in-
creasing evidence for a continuous relation be-
tween albuminuria and cardiovascular risk,
even at levels of albuminuria within the normal range (4).
In diabetes, the prevalence of microalbuminuria varies
from 20 to 40% (5–7), and prevention of microalbuminuria
was investigated in large-scale prospective studies (e.g.,
the BErgamo NEphrologic DIabetes Complications Trial)
(8). In the general population, microalbuminuria also
seems to be a common phenomenon. The Prevention of
Renal and Vascular Endstage Disease Study (9) reported
a prevalence of microalbuminuria of 6.6%, after excluding
diabetes and hypertension, which is in accordance with
other ﬁndings of several cross-sectional studies (10–12)
that reported a prevalence of 5–8% of microalbuminuria in
general “healthy” populations.
Albuminuria is considered to be the result of a mal-
function of the glomerular ﬁltration barrier, although fail-
ure of tubular reuptake of albumin also is discussed as
a contributor. The glomerular ﬁltration barrier consists of
three layers that separate the intravascular from the urine
space. These layers are the glomerular endothelium, which
is fenestrated; the glomerular basement membrane; and
the podocytes with its foot processes. Although the glo-
merular ﬁltration barrier was the object of intensive
studies for decades, the role and effects of the individual
layers on albuminuria remain controversial (13–15). How-
ever, currently there is increasing evidence that the glo-
merular endothelium also may play a signiﬁcant role in
glomerular permselectivity and, hence, genesis of albumin-
uria (14,16).
One of the most important mediators released by the
endothelium is nitric oxide (NO), which is generated by
a variety of NO synthases (NOSs), including endothelial
NOS (eNOS) (17). Endothelium-derived NO has been
widely used as general marker of endothelial function (18).
Altered production and release of NO (i.e., reduced basal
NO activity) (19) can be directly assessed by systemic in-
fusion of N
G-monomethyl-L-arginine (L-NMMA) in humans
and have been found to be decreased in renal disease (20).
A diabetic mouse model knockout of eNOS expression
resulted in signiﬁcantly increased albuminuria compared
with that in control mice (21). Genetic association studies
in humans have shown that eNOS polymorphisms that
potentially impair eNOS gene transcription and activity are
associated with an increased risk of diabetic nephropathy
(22,23).
Although the meaning of endothelial dysfunction in re-
lation to albuminuria has been discussed repeatedly, until
now no analysis on the change in albuminuria in response
to inhibition of NO, resulting in a reduction of basal NO
activity, has been carried out in humans. Therefore, as
a proof of concept, we tested in two study populations
the hypothesis that reduced NO activity causes albu-
minuria.
RESEARCH DESIGN AND METHODS
Subjects were recruited by advertising in local newspapers in the area of
Erlangen-Nürnberg, Germany, and eligible subjects were enrolled consecu-
tively in one of two subpopulations, according to their clinical characteristics.
Written informed consent was obtained prior to study inclusion. Study pro-
tocols were approved by the local ethics committee (University of Erlangen-
Nürnberg), and the study was conducted in accordance with the Declaration
of Helsinki and the principles of good clinical practice guidelines.
Study population A. The main inclusion criteria of study population A were
havingtype2diabetesandarterialhypertensiondeﬁnedasmeanseatedsystolic
blood pressure (SBP) 130–179 mmHg and/or diastolic blood pressure (DBP)
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ORIGINAL ARTICLE80–109 mmHg or being on antihypertensive medications. Other inclusion cri-
teria were normoalbuminuria or microalbuminuria and glomerular ﬁltration
rate (GFR) .1.34 mL/s. The main exclusion criteria were having poor di-
abetes control (A1C .9%); receiving thiazolidinediones and/or the initiation
of statins for at least 4 weeks prior to the commencement of the study;
having hypertension-related end-organ damage, such as proliferative reti-
nopathy and symptomatic cardiovascular disease; and being a smoker. An-
tihypertensive medication was paused for at least 2 weeks.
Study population B. Study population B was composed of patients with
hypercholesterolemia deﬁned ashavingafasting LDLcholesterollevelof .4.14
mmol/L and ,6.58 mmol/L and fasting triglycerides ,4.0 mmol/L, while not
receiving statins for at least 4 weeks before study inclusion. The main exclusion
criteria included having diabetes, micro- or macroalbuminuria, arterial hyper-
tension, homozygous familial hypercholesterolemia, and hyperlipoproteinamia
type III; showing evidence of having cardiovascular or renal disease; and being
a smoker. All had an estimated GFR of .1.34 mL/s and were free of any
cardiovascular medications.
Experimental protocol. All subjects were studied in the supine position at the
same time in the morning in a quiet and temperature-controlled room. Before
the experimental protocol was started, patients were advised to empty their
bladder. This urine was discarded. A constant infusion (250 mL/h) of saline was
administered throughout the protocol. After 115–120 min of rest, patients were
asked to urinate and basal urine was obtained. Thereafter, the NOS inhibitor
L-NMMA (Clinalfa, Läufelingen, Switzerland) was administered intravenously
as a bolus infusion (3 mg/kg body wt) over 5 min, followed by constant in-
fusion over 25 min with a rate of 0.05 mg/kg/min. Therefore, the total dose was
4.25 mg/kg body wt. At the end of the L-NMMA phase, urine was collected
again (L-NMMA sample). For safety reasons, an infusion of 100 mg/kg body
wt of L-arginine (6% L-arginine hydrochloride; University Hospital Pharmacy,
Erlangen, Germany) was infused to counteract L-NMMA–induced vasocon-
striction.
In parallel, renal hemodynamic parameters were determined by the con-
stant-infusion input-clearence technique with inulin (Inutest; Fresenius, Linz,
Austria) and sodium p-aminohippurate (Clinalpha, Basel, Switzerland) for GFR
and renal plasma ﬂow (RPF), respectively, as previously outlined in detail
(24). In brief, after a bolus infusion of inulin and p-aminohippurate over a
15-min period and a subsequent constant infusion over 105 min, a steady state
between the input and renal excretion of the tracer substances was reached,
and, in addition, the administration of the above-mentioned experimental
substance (L-NMMA) was started. Renal vascular resistance was calculated as
the product of mean arterial pressure (MAP) and 1-hematocrit divided by RPF.
Throughout the infusion protocol, blood pressure (SBP, DBP, and MAP) and
heart rate were monitored at ﬁxed intervals (every 5 min) by means of an
oscillometric device (Dinamap; Criticon, Norderstedt, Germany).
Measurement of urinary albumin and creatinine. All samples were cen-
trally measured by the laboratory of the University of Erlangen-Nürnberg,
according to established methods. In brief, urine albumin concentration was
measured by a turbidimetric method. The interassay coefﬁcient of variation
was 3.44%. Creatinine concentration in urine was measured photometrically
by the Jaffe method. The interassay coefﬁcient of variation was 2.03%. The
urine albumin-to-creatinine ratio (UACR) was calculated by dividing urinary
albumin by urinary creatinine.
Statistical analysis. Normal distribution of data was conﬁrmed by a
Kolmogorov-Smirnow test before further analysis. Normally distributed data
were compared by paired Student t tests and are expressed as means 6 SD.
Data of UACR were not normally distributed; therefore, medians and inter-
quartile ranges are reported. UACR values were log transformed before sta-
tistical analysis. Where indicated, a multiple stepwise regression analysis with
signiﬁcance levels of 0.05 for entry and 0.10 for removal of a variable at each
forward step was conducted. Two-tailed values of P , 0.05 were considered
statistically signiﬁcant. All analyses were performed using SPSS version 15.0
(SPSS, Chicago, IL).
RESULTS
The baseline clinical characteristics of the participants in
population A (n = 62) are given in Table 1. This population
comprised middle-aged patients with diabetes, hyperten-
sion, and partly elevated cholesterol levels, but all had
normal renal function. Of 62 subjects, 25 had low-grade
albuminuria (male subjects: .10 mg/g creatinine; female
subjects .15 mg/g creatinine) and 6 had microalbuminuria
(30–299 mg/g creatinine), but none had macroalbuminuria.
The baseline clinical characteristics of the subjects in
study populations B (n = 22) are given in Table 2. In this
group, patients had elevated LDL cholesterol levels, whereas
blood pressure, fasting glucose, and other baseline param-
eters were in the normal range. All subjects had a normal
kidney function. Only three patients had low-grade albu-
minuria, but none had micro- or macroalbuminuria.
Systemic hemodynamics in response to L-NMMA. In-
fusion of L-NMMA led to an increase in SBP (population A:
from 142 6 14 to 155 6 17 mmHg; population B: from
127 6 17 to 141 6 20 mmHg; both P , 0.001) and DBP
(population A: from 78 6 10 to 85 6 11 mmHg; population
B: from 75 6 9t o8 16 10 mmHg; both P , 0.001) and to
a decrease in heart rate (population A: from 66 6 10 to
62 6 10 bpm; population B: from 58 6 7t o5 46 7 bpm;
both P , 0.001). MAP, which is considered to be a param-
eter of renal perfusion pressure, increased in population A
(from 100 6 10 to 108 6 11 mmHg; P , 0.001) and in
population B (from 94 6 10 to 103 6 13 mmHg; P , 0.001).
Change in UACR in response to L-NMMA. There was
a signiﬁcant increase in the UACR in response to the
blockade of eNOS with L-NMMA in the hypertensive
patients with type 2 diabetes (baseline: 12.3 mg/g creati-
nine [6.4–19.1] vs. L-NMMA: 16.9 mg/g creatinine [8.9–28.3];
P = 0.001) (Fig. 1) and in patients with hypercholesterol-
emia (baseline: 7.7 mg/g creatinine [4.0–8.9] vs. L-NMMA:
7.9 mg/g creatinine [6.1–14.7]; P = 0.044) (Fig. 2).
TABLE 1
Baseline characteristics of the participants of study population A
Characteristics
Age (years) 59.6 6 8
Sex (male/female) 43/19
Weight (kg) 85.6 6 16
Height (cm) 171 6 10
BMI (kg/m
2) 29.2 6 4.9
Casual SBP (mmHg) 146 6 15
Casual DBP (mmHg) 84 6 11
Blood glucose (mmol/L) 8.55 6 2.5
Triglycerides (mmol/L) 1.85 6 1.2
Total cholesterol (mmol/L) 4.87 6 0.7
LDL cholesterol (mmol/L) 3.21 6 0.9
HDL cholesterol (mmol/L) 1.32 6 0.4
Serum creatinine (mmol/L) 69.8 6 8.8
GFR (mL/s) 2.37 6 0.4
Data are means 6 SD.
TABLE 2
Baseline characteristics of the participants of study population B
Characteristics
Age (years) 52.7 6 14
Sex (male/female) 15/7
Weight (kg) 80.5 6 16
Height (cm) 174 6 10
BMI (kg/m
2) 26.6 6 3.7
Casual SBP (mmHg) 128 6 15
Casual DBP (mmHg) 77 6 7
Blood glucose (mmol/L) 5.38 6 0.6
Triglycerides (mmol/L) 1.98 6 0.7
Total cholesterol (mmol/L) 7.20 6 0.9
LDL cholesterol (mmol/L) 4.66 6 0.6
HDL cholesterol (mmol/L) 1.55 6 0.4
Serum creatinine (mmol/L) 77.8 6 8.8
GFR (mL/s) 2.34 6 0.3
Data are means 6 SD.
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infusion also may led to an increased renal perfusion
pressure and thereby to elevated albumin excretion, we
performed additional analyses of our data. To assess the
inﬂuence of MAP changes attributed to L-NMMA infusion
as a potential confounding factor as well as altered renal
hemodynamics, multiple linear regression analyses were
performed. MAP change in response to L-NMMA infusion
was not related to the increase in log-transformed UACR
attributed to L-NMMA infusion in both study populations
(population A: b = 0.235, P = 0.304, and population B: b =
0.024, P = 0.949). Similarly, changes of SBP and DBP also
were not related to changes of log-transformed UACR after
L-NMMA infusion (P . 0.20, data not shown). Further-
more, in both populations there was no relation between
the change in RPF (population A: b = 20.006, P = 0.975,
and population B: b = 20.278, P = 0.522), change in GFR
(population A: b = 20.124, P = 0.698, and population B: b =
20.122, P = 0.606), change in ﬁltration fraction (GFR/RPF)
(population A: b = 20.165, P = 0.237, and population B: b =
0.054, P = 0.832), and change in renal vascular resistance
(population A: b = 0.119, P = 0.772, and population B: b =
0.182, P = 0.363) and the increase in log-transformed
UACR in response to L-NMMA infusion. Although not
fully determined, metabolic factors such as hyperglycemia,
A1C, and hyperlipidemia may inﬂuence endothelial per-
meability. However, neither fasting blood glucose and
A1C, respectively, nor elevated LDL cholesterol were re-
lated with either baseline UACR or the change of log-
transformed UACR in response to L-NMMA (P . 0.20, data
not shown).
DISCUSSION
Almost two decades ago, Deckert et al. (25) proposed
what usually has been cited as the Steno hypothesis, which
states that microalbuminuria reﬂects generalized vascular
damage. This hypothesis links impaired vascular endo-
thelial function to vascular leakage of albumin that, in
terms of the kidney, easily can be detected by measuring
urinary albumin excretion. Microalbuminuria may simply
reﬂect the speciﬁc renal manifestations of generalized
vascular dysfunction. Indeed, albuminuria was associated
with an increased systemic permeability of albumin in both
type 1 diabetes (26) and type 2 diabetes in some (27) but
not in all (28) studies as well as in clinically healthy sub-
jects (29). However, the underlying mechanisms of this
increased permeability remain to be fully elucidated. The
importance of NO for intact vascular function and endo-
thelial integrity has been thoroughly documented. Because
decreased bioavailability of NO is a major contributor to
endothelial function, we have investigated whether an
acute reduction of basal NO activity provokes albuminuria.
By measuring albuminuria both before and after sys-
temic infusion of L-NMMA, we could demonstrate that
impaired renal endothelial function leads to a signiﬁcant
increase of albuminuria in response to NOS inhibition with
L-NMMA. Our direct methodological approach proves, for
the ﬁrst time in humans, the previously proposed concept
that impaired basal NO activity, and thus endothelial dys-
function, is a major pathogenic mechanism that increases
the permeability of the vascular wall and hence the genesis
of albuminuria. Using a before-and-after design without
a control group may limit the assessment of the magnitude
of the observed effect. Nevertheless, our data suggest that
the change of UACR in response to inhibition of NO, re-
sulting in a reduction of basal NO activity, may serve as
a marker of endothelial function in the kidney, which can
be easily measured.
It is noteworthy that these ﬁndings were evident in both
hypertensive patients with type 2 diabetes and patients
with hypercholesterolemia but without hypertension and
type 2 diabetes. The change of MAP according to L-NMMA
was not related to the change of UACR according to
FIG. 1. UACR before and after systemic infusion of the NO inhibitor L-NMMA in study population A on a log-scaled axis.
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RPF), ruling out an impact of changes of blood pressure
and renal perfusion pressure on increased albumin ex-
cretion. We are aware that multiple regression analysis
is an indirect statistical approach to assess potential in-
ﬂuence of systemic and renal hemodynamic changes on
the change of log-transformed UACR attributed to L-NMMA
infusion, which, however, is one of the most accepted
methods to account for potential confounding factors
in vivo in humans.
Our ﬁndings are in line with animal models, genetic
studies, and large studies with prospective character. It
has been shown in a diabetic mouse model (lepr
db/db) that
genetic eradication of eNOS expression (eNOS
2/2) re-
sulted in an increase of albuminuria compared with con-
trol, lepr
db/db, or eNOS
2/2 mice (21). Moreover, induction
of diabetes in an inbred eNOS knockout animal model on
the CF57/BL6 background, which is known to be resistant
to nephropathy, has caused glomerular endothelial injury
and resulted in overt albuminuria (30). Sharma et al. (31)
have shown, using an in vitro approach and thereby ruling
out the effects of altered hemodynamics or circulating
cells of factors, that inhibition of NOS activity resulted in
an increased glomerular capillary permeability to albumin.
It has been suggested that inhibition of NOS could enhance
O2
2-mediated oxidative injury, which can be attenuated by
exogenous NO and/or by O2
2 scavengers. These ﬁndings
were supported by a similar approach, and it has been
concluded that NOS-catalyzed NO production is an im-
portant mechanism in regulating glomerular permeability
to albumin, which likely involves control of the bioavail-
ability of superoxide (32). In accordance, Giner et al. (33)
have reported elevated levels of markers of oxidative stress
in hypertensive patients with microalbuminuria compared
with those without microalbuminuria, and similar results
were reported from type 2 diabetic patients (34). Genetic
studies in humans have shown that eNOS polymorphisms
that potentially impair eNOS gene transcription and activity
are associated with an increased risk of diabetic nephrop-
athy (22,23).
In a small Japanese study (35), ~200 diabetic patients
with normo-, micro-, and macroalbuminuria were inves-
tigated. Percentage change of ﬂow-mediated dilation of
the brachial artery, to be in part related to endothelial
function and endogenous NO production, was signiﬁcantly
decreased in micro- and macroalbuminuric compared with
normoalbuminuric patients. Furthermore, ﬂow-mediated
vasodilation was signiﬁcantly correlated with the degree of
albuminuria. In the Hoorn Study (36), even after adjust-
ment for age, sex, baseline arterial diameter, and other
potential confounding factors, ﬂow-mediated vasodilation
was lower in the presence of microalbuminuria.
There are many large, prospective trials evaluating the
impact of therapeutic approaches to reduce microalbu-
minuria in diverse populations. These trials are focused on
cardiovascular events or on the progression of renal dis-
ease and not on an improvement of endothelial function.
Interestingly, it was shown that the therapeutic approaches
associated with lowering albuminuria (e.g., rev. in 37) also
are known to improve endothelial function.
In the two study populations, we found that NOS in-
hibition, as assessed by measuring UACR both before
and after the blockade of NOS with systemic infusion
of L-NMMA provokes albuminuria that is unrelated to
changes in the systemic circulation. Interestingly, this
ﬁnding was evident in patient groups prone to endothelial
dysfunction and albuminuria, and, therefore, ﬁndings can-
not be extrapolated to the general population. Thus, addi-
tional studies are necessary to evaluate whether acute
deterioration of endothelial function by reducing NO ac-
tivity causes an increase of albuminuria also in the general
population.
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